Actively Recruiting
Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2023-12-12
68
Participants Needed
1
Research Sites
338 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
CONDITIONS
Official Title
Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with metastatic non small cell lung cancer enrolled in the CRCHUM Lung Cancer Registry and PERa registry
- Able to provide written informed consent
- Eastern Cooperative Oncology Group performance status between 0 and 3
- Oligoprogression involving 1 to 5 extracranial lesions, each 5 cm or smaller, affecting 3 or fewer organs
- Oligoprogression while receiving immune checkpoint inhibitor or tyrosine kinase inhibitor therapy
- Patients with brain metastases allowed; brain lesions are not counted in the total number of progressive lesions
- All disease sites can be safely targeted with stereotactic ablative radiotherapy
- Patients with prior treated metastases eligible if prior ablation occurred before current systemic therapy
You will not qualify if you...
- Any lesion larger than 5 cm
- Pregnancy or breastfeeding
- Any medical condition that prevents radiotherapy or follow-up after radiotherapy
- Presence of spinal cord compression
- Metastatic disease invading the gastrointestinal tract (esophagus, stomach, small or large bowel)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
Research Team
S
Silvine Benth
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here